Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Clinical trial NCT00431210 · COMPLETED

Trial details

NCT number: NCT00431210
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Nasopharyngeal Carcinoma

Start date: 2007-02-01
Primary completion: 2015-06-30
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.